Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.
Roche’s Alzheimer’s antibody looks likely to join the scrapheap. But the company is determined to keep plugging away at the disease.
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
The company’s renal denervation system has failed in a crucial late-stage trial, just as an earlier version did eight years ago.
Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.